title: Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo.
abstract: Thirty-four patients with seasonal affective disorder, winter depression type (WD) were randomly distributed to receive the selective monoamine oxidase-A inhibitor moclobemide (400 mg daily) or placebo in a double-blind, parallel group study lasting for up to 14 weeks. Severity measures were the Montgomery-Asberg Depression Rating Scale (MADRS) extended with characteristic symptoms of WD; summed score of the "atypical" symptoms hypersomnia, hyperphagia and carbohydrate craving; and Clinical Global Impressions (CGI). After 3 weeks, patients with unsatisfactory response were switched to open moclobemide. Three patients on placebo dropped out before 3 weeks. Extended MADRS and CGI showed no significant difference between the groups at 3 weeks, whereas the atypical score was reduced significantly more on moclobemide than on placebo already after one week. Nonresponders after 3 weeks (9 of 16 on moclobemide and 7 of 15 on placebo) improved rapidly after being given open moclobemide. Predictor analysis showed a remarkably high negative correlation between improvement at 3 weeks (extended MADRS) and age in the placebo group and a strong, nonsignificant trend in the same direction in the moclobemide group. Dichotomizing the patients according to the median age (45 years) resulted in a somewhat better effect of moclobemide than placebo in the older age group. There were no significant differences in side effects between moclobemide and placebo.
authors.affiliation: Gaustad Hospital, Oslo, Norway.
authors.forename: O
authors.initials: O
authors.lastname: Lingjaerde
authors.forename: T
authors.initials: T
authors.lastname: Reichborn-Kjennerud
authors.forename: A
authors.initials: A
authors.lastname: Haggag
authors.forename: I
authors.initials: I
authors.lastname: Gärtner
authors.forename: K
authors.initials: K
authors.lastname: Narud
authors.forename: E M
authors.initials: EM
authors.lastname: Berg
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009664:Norway; D010555:Personality Inventory; D010789:Phototherapy; D016574:Seasonal Affective Disorder / Q000188:drug therapy* / Q000523:psychology; D012621:Seasons
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide